{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:51:09Z","timestamp":1772160669950,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Bullous pemphigoid (\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      ) is an autoimmune blistering disease that is characterized by formation of subepidermal bullae due to functional disturbance of the hemidesmosomal proteins on the keratinocytes at the basal membrane zone. In recent years, several studies have emphasized the important role of IgE autoantibodies in the pathogenesis of\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      . Consequently, a therapeutic approach using IgE depleting antibodies, such as a humanized monoclonal anti\u2010IgE antibody (e.g. omalizumab) may represent a new option for treatment of this autoimmune disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this paper, we report about the successful treatment of\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      with omalizumab in two patients and provide a review of the current literature on the relationship between IgE antibodies and this autoimmune blistering disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two patients with therapy\u2010resistant\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      were treated with humanized monoclonal anti\u2010IgE antibody omalizumab 300 mg subcutaneously every 3 weeks as corticosteroid\u2010sparing agent. Under this therapy, both patients experienced a significant improvement of skin condition and almost complete resolution of pruritus. The treatment was well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Until recently IgG autoantibodies against the basal membrane proteins\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      180 und\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      230 were considered to be causative in the pathogenesis of\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      . However, new\n                      <jats:italic>in vitro<\/jats:italic>\n                      studies as well as data from experimental mouse models have indicated that in addition to specific IgG, also IgE antibodies against\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      180 and\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      230 play a role in the development of this disease. Based on these new findings, new treatment modalities of\n                      <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n                      became possible.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.13758","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T23:42:49Z","timestamp":1467243769000},"page":"1778-1782","source":"Crossref","is-referenced-by-count":60,"title":["Successful treatment of bullous pemphigoid with omalizumab as corticosteroid\u2010sparing agent: report of two cases and review of literature"],"prefix":"10.1111","volume":"30","author":[{"given":"G.","family":"Balakirski","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology Universitiy Hospital of Aachen Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alkhateeb","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Universitiy Hospital of Aachen Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.F.","family":"Merk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Universitiy Hospital of Aachen Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leverkus","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Universitiy Hospital of Aachen Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Megahed","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Universitiy Hospital of Aachen Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06976_supp.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a180"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690130050009"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001050051001"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12072"},{"key":"e_1_2_5_8_1","first-page":"833","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Eming R","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13717"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1974.01630090016003"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12146.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90168-3"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03661.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2007.08.008"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.04.013"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10481.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700681"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700958"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8547-7"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001753"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.supplement_1.2103025"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.11.044"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1604"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10748.x"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.11.035"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2013.130642"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.053"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13758","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T08:12:22Z","timestamp":1695456742000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/jdv.13758"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13758","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726472950.793549786","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,29]]}}}